On January 27, 2026, the U.S. Food and Drug Administration (FDA) announced the launch of a new interactive, consumer-facing web tool, the Total Diet Study Interface (TDSi), alongside the publication of updated results from its Total Diet Study (TDS). The update includes newly released data from fiscal years 2021 and 2022, with comprehensive datasets covering fiscal years 2018 through 2022, and applies to foods representing the average U.S. consumer diet monitored under the TDS program.
Details of the Update
The FDA introduced the Total Diet Study Interface, a web-based platform designed to provide streamlined access to analytical findings on chemical contaminants and nutrients in foods. The interface consolidates multiple years of TDS data into a single, user-friendly environment, improving transparency and usability. The datasets include information on nutrients, elements, radionuclides, and pesticides in foods analyzed since 2018, with options for full dataset downloads to support research, compliance review, and risk assessment activities. The FDA also confirmed that the platform will be regularly updated as new TDS findings are released, supporting ongoing surveillance of cumulative dietary exposure.
Feedback Deadline
Not applicable. The FDA announcement does not specify a public consultation or feedback deadline.
Why It Matters
This update strengthens regulatory clarity and transparency by improving access to FDA food chemical safety and nutrition data through a centralized digital interface. Enhanced visualization tools, downloadable datasets, and continuous updates support efficient analysis and evidence-based decision-making while aligning with FDA’s oversight responsibilities. Importantly, the initiative improves data accessibility without introducing additional operational burden for industry stakeholders.
Who This Is Relevant For
This development is relevant for Regulatory Affairs, Quality Assurance, Legal and Compliance, R&D, patient safety groups, and commercial or marketing teams involved in food product oversight, nutrition research, and food safety monitoring across the U.S. market.
Next Steps
Organizations involved in food safety, nutrition, research, or regulatory affairs should review the Total Diet Study Interface to understand its functionality and the scope of available data, with particular attention to the newly released fiscal year results. Stakeholders may consider integrating the tool into existing monitoring, risk assessment, or research workflows, and should continue to track future FDA updates and communications related to the TDS platform to remain aligned with emerging insights.
As regulatory datasets become more accessible and continuously updated, organizations need efficient ways to monitor, interpret, and operationalize these insights across functions. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely, predictive, and actionable insights while streamlining compliance workflows and supporting informed decision-making across more than 160 countries. Learn more or book a demo now.
FAQs
What is the Total Diet Study Interface (TDSi)?
The Total Diet Study Interface is an interactive, web-based FDA tool that provides access to analytical data on nutrients and chemical contaminants in foods representing the average U.S. consumer diet.
Which data years are covered in the latest FDA update?
The update includes newly published results from fiscal years 2021 and 2022, with datasets spanning fiscal years 2018 through 2022.
What types of substances are included in the TDS datasets?
The datasets cover nutrients, elements, radionuclides, and pesticides analyzed in foods under the FDA’s Total Diet Study program.
How can RegASK help teams act on FDA food safety data?
RegASK helps regulatory, quality, and compliance teams monitor, contextualize, and integrate FDA updates like the TDS data into structured workflows, enabling faster risk assessment, clearer cross-functional alignment, and proactive compliance management.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
